Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients

Survivin’ Acute Myeloid Leukaemia—A Personalised Target for inv(16) Patients

Despite recent advances in therapies including immunotherapy, patients with acute myeloid leukaemia (AML) still experience relatively poor survival rates. The Inhibition of Apoptosis (IAP) family member, survivin, also known by its gene and protein name, Baculoviral IAP Repeat Containing 5 (BIRC5),...

Full description

Bibliographic Details
Main Authors: Jochen Greiner, Elliott Brown, Lars Bullinger, Robert K. Hills, Vanessa Morris, Hartmut Döhner, Ken I. Mills, Barbara-ann Guinn
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:International Journal of Molecular Sciences
Subjects:
BIRC5
overall survival
survivin
acute myeloid leukaemia
Core Binding Factor (CBF)
inv(16)
Online Access:https://www.mdpi.com/1422-0067/22/19/10482

Internet

https://www.mdpi.com/1422-0067/22/19/10482

Similar Items